A publication for alumni, donors, faculty and friends of UC Davis Health
Volume 14 • No 2 • Fall 2017
Noteworthy
They said it!
![Julie Schweitzer, Ph.D.](../images/2017-fall-noteworthy-tsi-schweitzer.jpg)
“School work is probably a lot less interesting than playing with the toy. You’re looking at competing activities here. It seems to me that it would be more distractive than helpful.”
![Paul Knoepfler, Ph.D.](../images/2017-fall-noteworthy-tsi-knoepfler.jpg)
“They were just saying, ‘Screw the rules, we’re just going to set up shop and put up a website and start injecting people with stem cells.’ I saw that as a threat, first to patients, but to the field as well.”
![John Olichney, M.D.](../images/2017-fall-noteworthy-tsi-olichney.jpg)
“We have a real knowledge gap in accurately knowing if dementia is different in minorities as compared to whites.”
![Simon Cherry, Ph.D.](../images/2017-fall-noteworthy-tsi-cherry.jpg)
“It will allow (pharmaceutical researchers) not just to ask, ‘Is my drug reaching a tumor?’ but ‘How much is in the liver?’ for example. So it can help us identify the best drug candidates, and we can hopefully have fewer failures in clinical trials.”
![Jan Nolta, Ph.D.](../images/2017-fall-noteworthy-tsi-nolta.jpg)
“The issue of so-called clinics offering unauthorized therapies that are listed on ClinicalTrials.gov is a big problem. Patients are led to believe that this listing makes the trials legitimate, but in fact it does not.”